Connect with us

Australia

Cynata Therapeutics aims for commercial production of cutting-edge STEM cell products

Cynata Therapeutics Ltd (ASX:CYP) is ready to move up to scalable production of its graft-versus-host disease (GvHD) drug after a clinical trial proved the safety and efficacy of the drug.

Cynata managing director and chief executive officer Dr Ross Macdonald told Proactive that showing the product had a desirable clinical effect in people was an excellent result for the company.

He said: “We achieved all of the study endpoints, demonstrating primarily the safety of the product but also efficacy, and therein lies one of the secrets to success in biotech land, which is demonstrating that the product or technology works in humans.”

The trial results included a 54% complete response rate, an 87% overall response rate and a greater than 87% survival rate of patients using the GvHD drug.

Not only is the technology safe and effective, it also bypasses complex and invasive surgeries for patients and hospitals, and lowers costs incurred by healthcare systems.

Cutting edge-technology[hhmc]..

Cynata Therapeutics Ltd (ASX:CYP) is ready to move up to scalable production of its graft-versus-host disease (GvHD) drug after a clinical trial proved the safety and efficacy of the drug.

Cynata managing director and chief executive officer Dr Ross Macdonald told Proactive that showing the product had a desirable clinical effect in people was an excellent result for the company.

He said: “We achieved all of the study endpoints, demonstrating primarily the safety of the product but also efficacy, and therein lies one of the secrets to success in biotech land, which is demonstrating that the product or technology works in humans.”

The trial results included a 54% complete response rate, an 87% overall response rate and a greater than 87% survival rate of patients using the GvHD drug.

Not only is the technology safe and effective, it also bypasses complex and invasive surgeries for patients and hospitals, and lowers costs incurred by healthcare systems.

Cutting edge-technology


Cynatas Cymerus technology overcomes the challenges of other production methods to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Macdonald said this put Cynata ahead of the pack in terms of commercial product development.

He said: “For a small Aussie company with a hundred million or so market cap to be the leader in the world in this area – and theres no dispute about that as for this particular type of cell therapy we are well and truly the leader as first company to complete a clinical study – its really a very exciting place to be.

“The technology provides a consistent manufacturing process – and that consistency and reproducibility is a vital element of successful drug product development.”

Fuji Film partnership


The company now has the full support and resources to achieve commercial production after signing on the dotted line with new partner, pharmaceutical giant, Fuji Film.

Macdonald said: “Australia is a great place for medical research and development, but it has some limitations when it comes to access to the amount of capital thats required to fully develop a drug product.

“Instead of trying to squeeze blood out of a stone, our strategy was to access the necessary resources through partnership.

“Fuji Film is very active in pharmaceuticals and in the manufacture of drug products and thats what drew us together.

“Its also consistent with our strategy of partnering our technology with global players who have the capacity and the access to resources that are necessary to ultimately bring our drug product to market.”

Cynata's Cymerus platform has potential applications across a wide range of diseases

Advancing the product to market


Fuji Film now has global rights to Cynatas first product, GvHD, and has already paid a US$3 million licence fee, bought US$3 million worth of stock at a 35% premium, and will pay further US$40 million in milestones plus a double-digit royalty on product sales.

Macdonald said: “This year they expect to start a phase two clinical trial.

“In Fuji Films hands, GvHD is expected to get to market sometime late in 2022 or early 2023.”

Further trials in 2020


Cynata has three fully-funded clinical trials upcoming, one is the phase two GvHD trial with Fuji Film, one is in Osteoarthritis (OA) which is funded by the Australian Government and one is in critical limb ischemia (CLI).

MacdonaRead More – Source

Continue Reading

Australia

De Grey Mining confident Hemi gold discovery has tier-1 production potential

De Grey Mining Limited (ASX:DEG) is Australias fastest-growing gold company, with the recent Hemi discovery in Western Australia and strong newsflow reflected by their market cap which is now around A$1 billion.

The Hemi discovery sits within the Mallina Gold Project and is a new style of mineralisation in the Pilbara region – intrusion-hosted, large-scale and close to the surface with grade continuity. It is also is largely underexplored with district-scale upside.

Relatively unexplored[hhmc]
While it has the same geological setting as the Yilgarn Craton, which has a very mature exploration history of more than 120 years, the Pilbara Craton has only been actively explored for the last 20 years.

The company is confident the region could host new shallow discoveries, unlike in the Yilgarn where new discoveries are only expected at depth.

This represents a significant opportunity for De Grey with the immediate growth strategy linked to increasing gold resource, extending deposits, an..

De Grey Mining Limited (ASX:DEG) is Australias fastest-growing gold company, with the recent Hemi discovery in Western Australia and strong newsflow reflected by their market cap which is now around A$1 billion.

The Hemi discovery sits within the Mallina Gold Project and is a new style of mineralisation in the Pilbara region – intrusion-hosted, large-scale and close to the surface with grade continuity. It is also is largely underexplored with district-scale upside.

Relatively unexplored


While it has the same geological setting as the Yilgarn Craton, which has a very mature exploration history of more than 120 years, the Pilbara Craton has only been actively explored for the last 20 years.

The company is confident the region could host new shallow discoveries, unlike in the Yilgarn where new discoveries are only expected at depth.

This represents a significant opportunity for De Grey with the immediate growth strategy linked to increasing gold resource, extending deposits, and making more Hemi-like discoveries close to established mining infrastructure in the region.

Hemi gold system


The Hemi system consists of three main deposit areas – Brolga, Aquila and Crow.

Large potential extensions to Aquila and Brolga have been identified from drilling with four rigs currently drilling extensional targets.

At Aquila, results include 33 metres at 1.5 g/t with the potential to extend the strike by 50% to more than 1,200 metres.

At Brolga, new extensions were recently reported with results from aircore drilling of 16 metres at 2.4 g/t with the southern extension currently around 1,000 metres long by about 200 metres wide and open.

Further aircore results are pending while more RC drilling is planned at both deposits.

At Crow deposit, the company is targeting an area up to 400 metres wide and 1,000 metres of strike with RC drilling planned and early-stage step-out drilling underway.

The company believes that further drilling will determine the scale of any future open pit mine which may have significant operating cost benefits.

Further drilling will determine the scale of any future open pit mine which may have significant operating cost benefits.

Brolga recoveries


Initial metallurgical test-work on Brolga mineralisation achieved recoveries of:

  • 96.3% from fresh rock using flotation, oxidation and carbon in leach (CIL); and
  • 93% in oxidised using CIL.

Results from a broader metallurgical test-work program are expected later in the current quarter.

Finding the next Hemi


De Grey has identified four lookalike mineralised intrusions within 10 kilometres of Hemi called Scooby, Antwerp, Shaggy and Alectroenas.

Two rigs are testing targets at Scooby and Antwerp and a detailed aeromagnetic survey has been completed over the prospective 30-kilometre zone.

Modelling, interpretation and a targeting study are well advanced and the company is now in the position to accelerate drill testing.

Regional intrusions


A total of eight known intrusions have been identified throughout the overall project area and seven are mineralised. Four of these are mineralised in the Hemi corridor.

More than 20 new magnetic features have beeRead More – Source

Continue Reading

Australia

S&P/ASX 200 drops 2.4% this week over worries of rising COVID-19 cases worldwide

S&P/ASX 200 (INDEXASX:XJO) closed 0.6% down today following news of another 288 COVID-19 cases in Victoria, a new daily record, and US futures also sliding into negative territory.

The biggest losses have been among the likes of energy and materials following a 2-3% fall in oil prices in overnight trade.

This weighed on local oil and gas producers with Oil Search (ASX:OSH) down the most with a loss of 4.1% while Woodside (ASX:WPL) and Origin Energy (ASX:ORG) dropped more than 2.2%.

COVID-19 update[hhmc]
306 new COVID-19 cases were recorded across Australia today, with Victoria, New South Wales, Western Australia and the Australian Capital Territory all seeing a rise in new infections.

In the US, more than 60,500 new COVID-19 infections were reported on Thursday, according to Reuters, setting a new one-day record.

As infections rose in 41 of the 50 states over the last two weeks, the US has become increasingly divided on issues such as the reopening of schools and businesses.

Top ..

S&P/ASX 200 (INDEXASX:XJO) closed 0.6% down today following news of another 288 COVID-19 cases in Victoria, a new daily record, and US futures also sliding into negative territory.

The biggest losses have been among the likes of energy and materials following a 2-3% fall in oil prices in overnight trade.

This weighed on local oil and gas producers with Oil Search (ASX:OSH) down the most with a loss of 4.1% while Woodside (ASX:WPL) and Origin Energy (ASX:ORG) dropped more than 2.2%.

COVID-19 update


306 new COVID-19 cases were recorded across Australia today, with Victoria, New South Wales, Western Australia and the Australian Capital Territory all seeing a rise in new infections.

In the US, more than 60,500 new COVID-19 infections were reported on Thursday, according to Reuters, setting a new one-day record.

As infections rose in 41 of the 50 states over the last two weeks, the US has become increasingly divided on issues such as the reopening of schools and businesses.

Top gainers


Todays top gainers on the ASX include VIP Gloves Ltd (ASX:VIP) (+10.00%), Artemis Resources Ltd (ASX:ARV) (+14.29%), Comet Resources Limited (ASX:CRL) (+13.33%), Esense-Lab Ltd (ASX:ESE) (+11.11%) and Archtis Ltd (ASX:AR9) (+12.50%).

Proactive news headlines:

Legend Minings ongoing hits of thick, massive nickel-copper sulphides are highly encouraging: Euroz


Legend Mining Ltd (ASX:LEG) recently added to the robust nature of Mawson prospect within the Rockford Project in WAs Fraser Range with an intersection of 4.5 metres at 3.05% nickel, 2.32% copper and 0.19% cobalt – the best grades to date. Euroz has reiterated its speculative buy rating for Legend with a price target of 30 cents per share (current price: 14 cents) after the recent high-grade drilling results.

Red River Resources sets new quarterly copper production record


Red River Resources Limited (ASX:RVR) has achieved record copper production at its Thalanga Operation in Northern Queensland for the quarter ending June 30, 2020. An increase in copper grade of ore milled to 1.0% and a record copper recovery to copper concentrate of 84.7% resulted in quarterly production of 2,697 tonnes of high-quality copper concentrate, compared to 2,310 tonnes in the previous quarter.

Andromeda Metals' maiden halloysite-kaolin reserve supports 26-year mine life


Andromeda Metals Ltds (ASX:ADN) 12.5 million tonnes maiden ore reserve at Careys Well deposit within the Poochera Halloysite-Kaolin Project JV in South Australia supports a 26-year mine life at an annual mining rate of 500,000 tonnes. The reserve of bright white kaolinised granite in the probable category comprises 15% halloysite and 78% kaolinite in the minus 45-micron fraction.

Bellevue Gold fields strong support for $100 million placement, reflecting quality of project


Bellevue Gold Ltd's (ASX:BGL) $100 million fully underwritten share placement has been strongly supported on the back of its impressive gold story with firm commitments from institutional investors for the issue of 100 million new shares at $1.00 per share. There was strong demand from domestic and offshore institutions with the book multiple times covered over the placement amount.

Creso Pharma wins second purchase order from Israels Univo for premium medicinal cannabis flower


Creso Pharma Ltds (Read More – Source

Continue Reading

Australia

Legend Minings ongoing hits of thick, massive nickel-copper sulphides are highly encouraging: Euroz

Legend Mining Ltd (ASX:LEG) recently added to the robust nature of Mawson prospect within the Rockford Project in WAs Fraser Range with an intersection of 4.5 metres at 3.05% nickel, 2.32% copper and 0.19% cobalt – the best grades to date.

Euroz has reiterated its speculative buy rating for Legend with a price target of 30 cents per share (current price: 14 cents) after the recent high-grade drilling results.

The stockbroker believes on-going hits of thick, massive nickel-copper sulphides are highly encouraging in terms of the evolution of a major new discovery.

The following is an extract from Euroz research update on Legend:

Assay Results from RKDD015 and RKDD018 at Mawson
Key Points[hhmc]

LEG has announced assay results received from diamond drillholes RKDD015 and RKDD018 at Mawson;
We highlight the consistency of these results with those that gave rise to the original discovery hole (#7) and that otherwise occur proximal to the ongoing following massive sulphide intersections ..

Legend Mining Ltd (ASX:LEG) recently added to the robust nature of Mawson prospect within the Rockford Project in WAs Fraser Range with an intersection of 4.5 metres at 3.05% nickel, 2.32% copper and 0.19% cobalt – the best grades to date.

Euroz has reiterated its speculative buy rating for Legend with a price target of 30 cents per share (current price: 14 cents) after the recent high-grade drilling results.

The stockbroker believes on-going hits of thick, massive nickel-copper sulphides are highly encouraging in terms of the evolution of a major new discovery.

The following is an extract from Euroz research update on Legend:

Assay Results from RKDD015 and RKDD018 at Mawson

Key Points

  • LEG has announced assay results received from diamond drillholes RKDD015 and RKDD018 at Mawson;
  • We highlight the consistency of these results with those that gave rise to the original discovery hole (#7) and that otherwise occur proximal to the ongoing following massive sulphide intersections as follows;
  • RKDD018:
    • 19.2m @ 1.69% Ni, 1.23% Cu, 0.09% from 97.9m (incl. 4.5m @ 3.05% Ni, 2.32% Cu, 0.19% Co from 103.7m;
    • 34.65m @ 0.51% Ni, 0.35% Cu, 0.03% Co from 130.7m;
  • The grades contained in the above 4.5m intercept in hole 18 are the best seen to date at Mawson;
  • RKDD018 was designed to test the eastern extension of sulphide mineralisation in both the upper disseminated and lower massive sulphide intervals intersected in RKDD008;
  • Of particular note was the “leopard textures” encountered. Per the Voiseys Bay analogue, leopard textures are considered to indicate close proximity to an ultramafic intrusive source;
  • RKDD015:
    • 73.5m @ 0.32% Ni, 0.29% Cu, 0.02% Co from 87.5m;
    • 24.3m @ 0.22%, Ni 0.26% Cu, 0.02% Co from 279m;
  • RKDD015 was designed to test the northern extension of massive sulphide mineralisation in RKDD011 and the eastern extension of the upper sulphide zone in RKDD007;
  • LEG is progressing its 3,000m RC drilling programme over the next month;
  • We anticipate an extension of the program with further positive results and incorporation of diamond tails where warranted, with diamond drilling to follow in a success case;
  • The aircore anomalism continues to build in the eastern shadow of the main gravity feature;
  • We note substantial infill on the previous update, that is exhibiting a coherent cluster of geochem anomalism immediately adjacent to the main gravity features;
  • Furthermore, 2D modelling of these gravity features suggest densities consistent with mafic and ultramafic packages that to date appear to be possible sRead More – Source
Continue Reading

Trending